Clinical Trial Results:
            Estudio multicéntrico aleatorizado, controlado con placebo, para evaluar la eficacia y la seguridad de eltrombopag en sujetos trombocitopénicos infectados por el virus de la hepatitis C (VHC) que, por lo demás, resulten elegibles para iniciar tratamiento antiviral (peginterferón alfa-2a más ribavirina)
Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral therapy (peginterferon alfa-2a plus ribavirin)
ENABLE 1 (Eltrombopag to INitiate and Maintain Interferon Antiviral Treatment to Benefit Subjects with Hepatitis C related Liver DiseasE)
    
| 
                 Summary 
         | 
        |
    EudraCT number  | 
        2006-004946-17 | 
    Trial protocol  | 
        ES FR BE NL IT CZ GB SK DE | 
    Global completion date  | 
        
                                    31 Mar 2011
                             
         | 
    
| 
                 Paediatric regulatory details 
         | 
        |
    Is the trial part of an agreed EMA paediatric investigation plan?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
| 
                 Results information 
         | 
        |
    Results version number  | 
        v1(current) | 
    This version publication date  | 
        
                                    08 Jul 2016
                             
         | 
    
    First version publication date  | 
        
                                    08 Jul 2016
                             
         | 
    
    Other versions  | 
        |
    Summary report(s)  | 
                                103922-FDAAA-Result-Summary | 
    
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.